The population-level costs of immunosuppression medications for the treatment of glomerulonephritis are increasing over time due to changing patterns of practice
| Autor: | Jagbir Gill, Scott Klarenbach, Sean J. Barbour, Clifford Lo, Gabriela Espino-Hernandez, John Feehally, Sharareh Sajjadi |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male Canada medicine.medical_specialty Databases Factual Cost effectiveness 030232 urology & nephrology Lupus nephritis Azathioprine Nephropathy 03 medical and health sciences Glomerulonephritis 0302 clinical medicine Focal segmental glomerulosclerosis Membranous nephropathy Internal medicine medicine Humans 030212 general & internal medicine Practice Patterns Physicians' Intensive care medicine Retrospective Studies Transplantation business.industry Retrospective cohort study Middle Aged medicine.disease Nephrology Cohort Female business Immunosuppressive Agents medicine.drug |
| Zdroj: | Nephrology Dialysis Transplantation. 33:626-634 |
| ISSN: | 1460-2385 0931-0509 |
| DOI: | 10.1093/ndt/gfx185 |
| Popis: | Background Immunosuppression (IS) is the main treatment for most types of glomerulonephritis (GN). Quantifying the cost of IS is necessary to ensure equitable access to therapies and optimal health outcomes, but the real-world cost of IS treatment for GN is largely unknown. We examined temporal changes in the population-level IS medication costs for GN over a 14-year period in a large Canadian province. Methods We linked a provincial pathology database (containing all GN cases from 2000 to 2012) with renal and medication administrative databases to capture clinical characteristics and IS medications, with follow-up until 2013. The primary outcome (mean IS medication cost per treated patient each year) was evaluated for trends over time. Results The cohort included 2983 GN patients followed for a mean of 5.7 years. The yearly per-patient medication cost increased 6.8-fold from $205 to $1394 (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|